Edition:
United Kingdom

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

7.76USD
3:36pm BST
Change (% chg)

$-0.20 (-2.51%)
Prev Close
$7.96
Open
$8.00
Day's High
$8.00
Day's Low
$7.62
Volume
47,028
Avg. Vol
126,902
52-wk High
$9.49
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Galectin Therapeutics Q1 Loss Per Share $0.12
Friday, 11 May 2018 

May 11 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.12.GALECTIN THERAPEUTICS - HAS ENOUGH CASH TO FUND CURRENTLY PLANNED OPERATIONS, RESEARCH & DEVELOPMENT ACTIVITIES THROUGH AT LEAST MARCH 31, 2019.  Full Article

Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019.GALECTIN THERAPEUTICS INC - BORROWINGS UNDER CREDIT LINE ARE AT COMPANY'S DISCRETION THROUGH DECEMBER 31, 2018.  Full Article

Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 2B NASH-CX TRIAL OF ITS PROPRIETARY COMPOUND GR-MD-02.GALECTIN - PHASE 2B TRIAL NASH-CX SHOWED STATISTICALLY SIGNIFICANT RESULTS IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG VERSUS PLACEBO.GALECTIN - FOR MAJOR SECONDARY ENDPOINT ASSESSMENT OF LIVER BIOPSY, SAW STATISTICALLY SIGNIFICANT EFFECT OF TREATMENT TO IMPROVE HEPATOCYTE BALLOONING.GALECTIN - THERE WAS STATISTICALLY SIGNIFICANT REDUCTION IN DEVELOPMENT OF NEW ESOPHAGEAL VARICES IN PATIENTS WITHOUT VARICES AT BASELINE.GALECTIN-THERE WAS POSITIVE TREND IN TOTAL GROUP,BUT DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG​‍​.  Full Article

Galectin Therapeutics To Present Results From Phase 2B Nash-Cx Trial On December 5, 2017
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS TO PRESENT RESULTS FROM PHASE 2B NASH-CX TRIAL ON DECEMBER 5, 2017.  Full Article

Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Galectin Therapeutics Inc :Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial.  Full Article

Galectin Therapeutics posts qtrly loss per share $0.13‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Galectin Therapeutics Inc :Galectin Therapeutics Inc - Qtrly loss per share $0.13‍​.Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​.Galectin Therapeutics Inc - ‍Company is funded through february 2018, which is sufficient to report top line data of NASH-CX phase 2B clinical trial​.Galectin Therapeutics - Believes it has sufficient cash to fund currently planned operations and research, development activities through Dec. 31, 2017​.Galectin Therapeutics Inc - ‍As of September 30, 2017, company had $7.0 million of non-restricted cash and cash equivalents​.  Full Article

Galectin Therapeutics Q2 loss per share $0.20
Tuesday, 9 Aug 2016 

Galectin Therapeutics Inc : Q2 loss per share $0.20 . Galectin therapeutics reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Believes it has sufficient cash to fund currently planned operations, research and development activities through june 30, 2017.  Full Article

Galectin Therapeutics quarterly loss per share $0.20
Tuesday, 9 Aug 2016 

Galectin Therapeutics Inc : Believes it has sufficient cash to fund currently planned operations and research, development activities through June 30, 2017 . Quarterly loss per share $0.20 . Quarterly loss per share $0.20 . Top-Line data from Nash-Fx trial in Nash patients with advanced fibrosis expected to be reported by end of Sept - sec filing .Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE